Liquid Embolic Agent Market

Liquid Embolic Agent Market Analysis and Forecast by Fact.MR

• The global liquid embolic agent market is estimated at US$ 279.9 million in 2025 and is forecast to expand at a CAGR of 10.3% to reach US$ 822.9 million by 2036.
• The liquid embolic agent category spans non adhesive liquid embolic agents, ethylene vinyl alcohol copolymer based agents, dimethyl sulfoxide based systems, and related therapeutic approaches addressing polymer based systems and ethylene vinyl alcohol copolymer.
• Growth reflects rising disease prevalence, expanding clinical evidence, and increasing healthcare access across both developed and emerging markets.
• Regulatory approvals, payer coverage expansion, and physician familiarity with newer therapeutic mechanisms are contributing to sustained demand across the forecast period.

Summary of Liquid Embolic Agent Market

• Market Snapshot
  • In 2025, the global Liquid Embolic Agent Market was valued at approximately USD 279.9 million.
  • The market is estimated to reach USD 308.7 million in 2026 and is projected to attain USD 822.9 million by 2036.
  • The liquid embolic agent market is likely to expand at a CAGR of 10.3% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 514.1 million between 2026 and 2036.
  • Non Adhesive Liquid Embolic Agents is expected to lead the product segment in 2026.
  • India (12.2%) and China (11.3%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Rising disease prevalence and improving diagnosis rates are expanding the addressable patient population across both developed and emerging healthcare systems.
  • Growing clinical evidence and real-world data supporting treatment efficacy are strengthening physician confidence and prescribing patterns in specialty care settings.
  • Expanding regulatory approvals and payer coverage decisions are improving patient access and reducing out-of-pocket treatment barriers in major markets.
  • Increasing investment in specialty pharmacy infrastructure and patient support programs is supporting treatment initiation and long-term adherence.
• Product and Segment View
  • Non Adhesive Liquid Embolic Agents is expected to lead the product segment in 2026, supported by established clinical adoption and broad availability.
  • Polymer Based Systems is anticipated to account for the largest share of the composition segment, reflecting concentrated treatment demand.
  • Neurovascular Disorders is projected to lead the application segment, supported by clinical preference and treatment protocol alignment.
  • Key segmentation includes:
    • Product: Non Adhesive Liquid Embolic Agents, Ethylene Vinyl Alcohol Copolymer Based Agents, Dimethyl Sulfoxide Based Systems, Precipitating Hydrophobic Injectable Liquid Systems, Adhesive Liquid Embolic Agents
    • Composition: Polymer Based Systems, Ethylene Vinyl Alcohol Copolymer, Polyvinyl Alcohol Derivatives, Acrylic Based Systems, Cyanoacrylate Formulations
    • Application: Neurovascular Disorders, Arteriovenous Malformations, Intracranial Aneurysms, Dural Arteriovenous Fistulas, Peripheral Vascular Disorders
    • End Use: Hospitals, Tertiary Care Hospitals, Specialty Neurosurgical Centers, Ambulatory Surgical Centers, Day Care Surgical Units
    • Delivery Technique: Catheter Based Delivery, Microcatheter Delivery Systems, Guided Catheter Navigation, Image Guided Procedures, Fluoroscopy Guided Embolization
  • These systems enable:
    • Targeted therapeutic intervention in specific disease pathways
    • Patient-specific treatment optimization and adherence support
    • Clinical outcome monitoring and long-term disease management
• Geography and Competitive Outlook
  • North America is a major market, supported by established healthcare infrastructure, strong payer coverage, and high treatment adoption rates.
  • Europe is expected to maintain steady growth, supported by structured market access frameworks and specialty treatment networks.
  • Asia Pacific is emerging as a growth region, with expanding healthcare investment and rising clinical awareness supporting demand.
  • India (12.2%) and China (11.3%) are the fastest-growing country markets during the forecast period.
  • Key companies include Medtronic plc, Johnson & Johnson (CERENOVUS), B. Braun SE, Terumo Corporation, Boston Scientific Corporation.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The liquid embolic agent market is entering a phase where growth depends on geographic expansion, payer negotiations, and real-world evidence generation. Markets with structured reimbursement pathways are absorbing demand faster. Companies combining strong clinical evidence with effective distribution are capturing disproportionate share. The next growth layer depends on how manufacturers address access barriers in mid-income markets while defending pricing in established geographies.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Rising prevalence of polymer based systems and ethylene vinyl alcohol copolymer conditions and improving diagnosis rates are expanding the addressable patient population, driving demand for non adhesive liquid embolic agents, ethylene vinyl alcohol copolymer based agents, dimethyl sulfoxide based systems across both developed and emerging healthcare systems.
• Growing clinical evidence, expanding real-world outcome data, and physician confidence in liquid embolic agent therapeutic mechanisms are strengthening prescribing patterns and supporting treatment uptake in specialty care settings.
• Expanding regulatory approvals across major markets and broadening payer coverage for non adhesive liquid embolic agents, ethylene vinyl alcohol copolymer based agents, dimethyl sulfoxide based systems are reducing access barriers and supporting patient enrolment in long-term treatment programmes.

Key Market Constraints

• High treatment costs for non adhesive liquid embolic agents, ethylene vinyl alcohol copolymer based agents, dimethyl sulfoxide based systems and reimbursement variability across markets create access barriers, particularly in price-sensitive healthcare systems managing polymer based systems and ethylene vinyl alcohol copolymer populations.
• Limited availability of specialised liquid embolic agent treatment centres and trained clinicians in emerging markets constrains adoption outside major metropolitan and academic medical centres.
• Lengthy regulatory approval timelines and complex market access negotiations for newer non adhesive liquid embolic agents, ethylene vinyl alcohol copolymer based agents, dimethyl sulfoxide based systems formulations in certain geographies delay commercial availability and patient uptake.

Key Opportunity Areas

• Label expansion of non adhesive liquid embolic agents, ethylene vinyl alcohol copolymer based agents, dimethyl sulfoxide based systems into adjacent indications and underserved patient subgroups within the polymer based systems and ethylene vinyl alcohol copolymer space is creating incremental revenue potential beyond current approved uses.
• Growing healthcare infrastructure investment in emerging markets is expanding the addressable liquid embolic agent treatment population, particularly in regions with rising clinical awareness and diagnostic capacity.
• Development of combination therapies, next-generation formulations, and optimised treatment protocols for polymer based systems and ethylene vinyl alcohol copolymer is supporting deeper market penetration and share capture in established geographies.

Segment-wise Analysis of the Liquid Embolic Agent Market

• Non Adhesive Liquid Embolic Agents is expected to lead the product segment in 2026, supported by established adoption, broad clinical utility, and availability across major markets.
• Polymer Based Systems is anticipated to account for the largest share of the composition segment, reflecting concentrated treatment demand and clinical prioritization.
• Catheter Based Delivery is projected to lead the delivery technique segment, supported by established treatment infrastructure and prescribing patterns.

The liquid embolic agent market is segmented by product, composition, application, end use, delivery technique, and region. By product, the market covers non adhesive liquid embolic agents, ethylene vinyl alcohol copolymer based agents, dimethyl sulfoxide based systems, precipitating hydrophobic injectable liquid systems. By composition, coverage includes polymer based systems, ethylene vinyl alcohol copolymer, polyvinyl alcohol derivatives, acrylic based systems. Non Adhesive Liquid Embolic Agents leads by value in the near term due to established demand, while emerging segments are expected to gain share over the forecast period.

Which Product Segment Leads the Liquid Embolic Agent Market?

Non Adhesive Liquid Embolic Agents is estimated to account for the largest share of the product segment in 2026. Demand is concentrated in established treatment settings where clinical evidence, physician familiarity, and payer coverage support continued adoption. The segment benefits from broad availability across specialty and general healthcare channels.

The ethylene vinyl alcohol copolymer based agents sub-segment is also gaining traction as clinical protocols evolve and treatment guidelines incorporate newer approaches, reflecting expanding indications and improving evidence bases.

Which Composition Segment Leads the Liquid Embolic Agent Market?

Polymer Based Systems is expected to lead the composition segment in 2026, reflecting the largest patient population and deepest clinical evidence base. Demand is supported by established diagnosis pathways, treatment protocols, and payer coverage across major geographies.

Ethylene Vinyl Alcohol Copolymer represent a growing portion of demand, supported by expanding clinical research and regulatory attention, diversifying the revenue base over the forecast period.

Which End Use Segment Leads the Liquid Embolic Agent Market?

Hospitals is anticipated to lead the end use segment in 2026, supported by clinical preference and established infrastructure across major healthcare settings.

Alternative end use options are gaining share as treatment settings diversify and home-based care options expand, supporting broader access.

Which Product Trend is Shaping the Next Phase of Growth in the Liquid Embolic Agent Market?

Ethylene Vinyl Alcohol Copolymer Based Agents are not yet the largest segment, but they are emerging as a growth area within the liquid embolic agent market. Their share is projected to rise as clinical evidence strengthens, regulatory approvals expand, and treatment protocols increasingly incorporate newer mechanisms. This is relevant for patient populations where existing options have not fully addressed treatment goals.

The shift toward newer approaches reflects changing clinical and commercial expectations. Providers and payers are evaluating treatment value based on long-term outcomes, patient convenience, and total cost of care. Products offering differentiated mechanisms or improved adherence profiles are moving from niche positions into more central roles within the treatment pathway.

Regional Outlook Across Key Markets

• India leads growth at 12.2%, supported by expanding healthcare access and rising treatment adoption.
• North America shows stable growth, with established healthcare infrastructure and strong payer coverage supporting continued demand.
• Europe maintains steady adoption, with structured market access frameworks and specialty treatment networks supporting growth.
• Asia Pacific is emerging as a growth region, with healthcare investment and rising clinical awareness creating incremental demand.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for Liquid Embolic Agent in India

Private healthcare investment and expanding urban tertiary care networks shape demand for non adhesive liquid embolic agents, ethylene vinyl alcohol copolymer based agents, dimethyl sulfoxide based systems in India. Ayushman Bharat coverage expansion and growing physician awareness in metropolitan centers are supporting adoption of specialty treatments.

• Tier-2 and tier-3 city hospital expansion is broadening the addressable patient base.
• Cost-effectiveness requirements in public health procurement shape product selection and pricing.

China Liquid Embolic Agent Demand Trends

The scale of hospital infrastructure investment in China is generating procurement volume for non adhesive liquid embolic agents, ethylene vinyl alcohol copolymer based agents, dimethyl sulfoxide based systems. Government push for technology self-sufficiency and domestic manufacturing capacity are reshaping supply chain dynamics.

• Volume-based procurement negotiations concentrate purchasing power and drive competitive pricing.
• Urban tertiary hospital expansion supports growing diagnosis rates and treatment initiation.

Liquid Embolic Agent Growth Assessment in Brazil

ANVISA regulatory processes and SUS public health system procurement determine access for non adhesive liquid embolic agents, ethylene vinyl alcohol copolymer based agents, dimethyl sulfoxide based systems in Brazil. Price control mechanisms and local manufacturing incentives influence both product availability and competitive positioning.

• SUS procurement programs and CONITEC assessments shape public sector treatment access.
• Private healthcare networks in southeastern states support specialty prescribing and adoption.

USA Liquid Embolic Agent Market Growth Outlook

Demand for non adhesive liquid embolic agents, ethylene vinyl alcohol copolymer based agents, dimethyl sulfoxide based systems in the USA is concentrated in specialty care centers and academic medical systems. Inflation Reduction Act provisions and evolving payer coverage models are reshaping pricing dynamics across the treatment landscape.

• Hospital system consolidation is centralizing procurement decisions for specialty products.
• Insurance coverage expansion for approved therapies supports patient access and volume growth.

Liquid Embolic Agent Demand Analysis in UK

NICE health technology assessments and NHS procurement frameworks shape demand for non adhesive liquid embolic agents, ethylene vinyl alcohol copolymer based agents, dimethyl sulfoxide based systems in the UK. Post-Brexit regulatory divergence and specialty commissioning pathways influence both market access timelines and formulary placement.

• NICE appraisal outcomes determine NHS commissioning decisions and patient access schemes.
• Specialty referral networks and regional treatment centers concentrate prescribing volume.

Germany Liquid Embolic Agent Opportunity Outlook

Demand for non adhesive liquid embolic agents, ethylene vinyl alcohol copolymer based agents, dimethyl sulfoxide based systems in Germany is shaped by structured health technology assessment processes and national reference pricing. The GKV system and hospital consolidation trends influence both formulary placement and procurement volumes.

• EU MDR compliance creates regulatory alignment for parallel access across neighboring markets.
• Reference pricing and budget impact assessments shape commercial positioning and payer negotiations.

Liquid Embolic Agent Expansion Trajectory in Japan

PMDA approval pathways and NHI pricing revisions shape demand for non adhesive liquid embolic agents, ethylene vinyl alcohol copolymer based agents, dimethyl sulfoxide based systems in Japan. An aging population profile and established preference for domestic suppliers influence both therapy adoption rates and supply chain positioning.

• NHI price revisions and biennial repricing cycles affect commercial sustainability.
• Aging demographics increase prevalence of conditions requiring specialty care and sustained treatment.

Competitive Benchmarking and Company Positioning

Liquid Embolic Agent Market Analysis By Company

• Medtronic plc, Johnson & Johnson (CERENOVUS), B. Braun SE, Terumo Corporation hold established positions in the global liquid embolic agent market through broad product portfolios, regulatory approvals, and commercial infrastructure.
• Boston Scientific Corporation, Meril Life Sciences Pvt. Ltd., GEM Srl, Balt Group participate across specific market segments, geographic regions, and distribution channels with competition shaped by clinical evidence and pricing strategy.
• Competition centers on clinical differentiation, market access capability, and commercial execution, with Medtronic plc accounting for approximately 17% of global market share.

Medtronic plc, Johnson & Johnson (CERENOVUS), B. Braun SE, Terumo Corporation hold established positions in the global liquid embolic agent market through broad product portfolios, regulatory approvals across major markets, and established commercial infrastructure supporting sustained market presence.

Boston Scientific Corporation, Meril Life Sciences Pvt. Ltd., GEM Srl, Balt Group, Sirtex Medical (BlackSwan Vascular, Inc.), INVAMED Research & Development Inc. participate across specific therapeutic segments, geographic markets, and distribution channels, with competition shaped by clinical evidence depth, pricing strategy, and payer access positioning.

The competitive landscape is moderately fragmented, with Medtronic plc accounting for approximately 17% of global market share. Competition centers on clinical differentiation, geographic market access, and commercial execution.

Key Companies in the Liquid Embolic Agent Market

• Medtronic plc, Johnson & Johnson (CERENOVUS), B. Braun SE, Terumo Corporation are among the leading players in the liquid embolic agent market, supported by established product portfolios, strong commercial presence, and regulatory approvals across major markets.
• Boston Scientific Corporation, Meril Life Sciences Pvt. Ltd., GEM Srl, Balt Group hold positions across specific therapeutic areas, geographic markets, and distribution networks, contributing to a competitive market structure.
• Sirtex Medical (BlackSwan Vascular, Inc.), INVAMED Research & Development Inc. maintain relevance through focused product offerings, regional presence, and specialized capabilities within the broader market.

Recent Industry Developments

• Medtronic plc - Geographic Expansion / Market Access (2026)
  • Medtronic plc expanded commercial availability of its liquid embolic agent portfolio into additional markets, strengthening geographic coverage and patient access across underserved regions. The expansion supports broader treatment uptake and aligns with the company's long-term growth strategy in the polymer based systems category.
• Johnson & Johnson (CERENOVUS) - Clinical Program Advancement / Pipeline Update (2025)
  • Johnson & Johnson (CERENOVUS) reported progress in its clinical development program targeting ethylene vinyl alcohol copolymer, supporting potential portfolio expansion in the liquid embolic agent market. The advancement reflects continued investment in clinical evidence generation and therapeutic differentiation.
• B. Braun SE - Distribution Partnership / Channel Expansion (2025)
  • B. Braun SE entered into a distribution partnership to strengthen market access and availability of its liquid embolic agent products across key growth markets. The partnership supports penetration in regions where specialty distribution infrastructure is still developing.

Leading Companies Shaping the Liquid Embolic Agent Market

• Medtronic plc
• Johnson & Johnson (CERENOVUS)
• B. Braun SE
• Terumo Corporation
• Boston Scientific Corporation
• Meril Life Sciences Pvt. Ltd.
• GEM Srl
• Balt Group
• Sirtex Medical (BlackSwan Vascular, Inc.)
• INVAMED Research & Development Inc.

Sources and Research References

• Medtronic plc. Product portfolio and market activity updates.
• Johnson & Johnson (CERENOVUS). Clinical development and commercial expansion updates.
• B. Braun SE. Distribution and market access updates.
• Industry association statistics, regulatory agency publications, clinical trial registries, and company product catalogs.
• Primary interviews with manufacturers, distributors, clinicians, payers, and institutional end users.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Liquid Embolic Agent Market?
• How fast is the liquid embolic agent market expected to grow between 2026 and 2036?
• Which product segment is likely to lead the market by 2026?
• Which composition segment is expected to account for the highest demand by 2026?
• What factors are supporting demand globally?
• How is the shift toward newer treatment approaches influencing the market?
• Why is India emerging as a fast-growing market?
• How are regulatory and reimbursement conditions supporting demand in key geographies?
• Which countries are projected to show the fastest growth through 2036?
• What is supporting market expansion in India, China, and Brazil?
• Who are the key companies active in the Liquid Embolic Agent Market?
• How does Fact.MR estimate and validate the market forecast?

Liquid Embolic Agent Market Definition

The liquid embolic agent market covers non adhesive liquid embolic agents, ethylene vinyl alcohol copolymer based agents, dimethyl sulfoxide based systems used across polymer based systems, ethylene vinyl alcohol copolymer, polyvinyl alcohol derivatives applications. The scope includes global and regional forecasts for 2026 to 2036 across product, composition, application, end use, delivery technique, and region.

Liquid Embolic Agent Market Inclusions

• The scope covers global and regional market size and forecasts for 2026 to 2036 across product, composition, application, end use, delivery technique, and region.
• It includes regional demand analysis across major geographies, based on factors such as disease prevalence, treatment access, regulatory conditions, and clinical adoption patterns.
• The report includes competitive landscape analysis covering product portfolios, pricing strategy, geographic reach, and distribution positioning of leading players.
• It covers technology trends, market drivers and constraints, and the regulatory environment shaping demand across major markets.

Liquid Embolic Agent Market Exclusions

• The scope excludes general healthcare products and services not specifically related to liquid embolic agent applications.
• It excludes investigational therapies and compounds in pre-clinical or early-stage development without commercial availability during the forecast period.
• The report excludes compounded or unlicensed preparations without commercial market visibility.
• It also excludes diagnostic devices, screening tools, and support services sold independently of therapeutic products.

Liquid Embolic Agent Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 120+ secondary sources and benchmarks 65+ company product portfolios.
• Market sizing covers 30+ countries through a demand-side model with top-down validation.
• Key inputs include disease prevalence, treatment rates, pricing benchmarks, and regulatory timelines.
• Primary validation includes 25+ interviews across manufacturers, distributors, clinicians, and payers.
• Final estimates go through trade-flow checks, sales-pattern review, and sensitivity testing.